NEXICLON XR (nda022500)- (EQ 0.17MG BASE,EQ 0.26MG BASE)

Generic Name	CLONIDINE	Innovator	ATHENA
Dosage	EQ 0.17MG BASE,EQ 0.26MG BASE
ParaIV Filing	No	505(b)2 Filing	Yes
Last Patent Expiry	2031-Sep-08	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	NEXICLON XR is a central alpha-adrenergic agonist indicated for: • Treatment of hypertension.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 0.17MG BASE	**	**	-	-	-
EQ 0.26MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of NEXICLON XR